Literature DB >> 26755525

Corrigendum to: Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study.

.   

Abstract

Entities:  

Year:  2016        PMID: 26755525      PMCID: PMC4708923          DOI: 10.1093/jrr/rrv096

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


× No keyword cloud information.
Corrigendum to: Ariga T, Toita T, Kato S, et al. Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study. J Radiat Res 2015 Sep; 56(5): 841–8. In the article “Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study.”, the affiliation of two authors, i.e. of Dr. Shingo Kato and Dr. Teruki Teshima were incomplete. The full and correct affiliations are follows: Takuro Ariga1, Takafumi Toita1*, Shingo Kato2,21, Tomoko Kazumoto3, Masaki Kubozono4, Sunao Tokumaru5, Hidehiro Eto6, Tetsuo Nishimura7, Yuzuru Niibe8, Kensei Nakata9, Yuko Kaneyasu10,22, Takeshi Nonoshita11, Takashi Uno12, Tatsuya Ohno13, Hiromitsu Iwata14, Yoko Harima15, Hitoshi Wada16, Kenji Yoshida17, Hiromichi Gomi18, Hodaka Numasaki19, Teruki Teshima19,23, Shogo Yamada4 and Takashi Nakano20 1Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa, 903–0215, Japan 2Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan 3Department of Radiation Oncology, Saitama Cancer Center, Saitama, Japan 4Department of Radiation Oncology, Tohoku University School of Medicine, Sendai, Japan 5Department of Radiology, Saga University, Saga, Japan 6Department of Radiology, Kurume University Hospital, Fukuoka, Japan 7Division of Radiation Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan 8Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Kanagawa, Japan 9Department of Radiology, Sapporo Medical University, Sapporo, Japan 10Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan 11Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan 12Department of Diagnostic Radiology and Radiation Oncology, Chiba University Graduate School of Medicine, Chiba, Japan 13Gunma University Heavy Ion Medical Center, Gunma University, Gunma, Japan 14Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Aichi, Japan 15Department of Radiology, Takii Hospital, Kansai Medical University, Osaka, Japan 16Department of Radiation Oncology, Miyagi Cancer Center, Miyagi, Japan 17Division of Radiation Oncology, Kobe University Graduate School of Medicine, Hyogo, Japan 18Department of Radiation Oncology, St Marianna University, School of Medicine, Kanagawa, Japan 19Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Osaka, Japan 20Department of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan 21Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan 22Department of Radiation Oncology, National Hospital Organization, Fukuyama Medical Center, Hiroshima, Japan 23 Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan *Corresponding author. Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, 207 Uehara, Nishihara-cho We sincerely apologize for this inconvenience.
  1 in total

1.  Long noncoding RNA ZNF667-AS1 reduces tumor invasion and metastasis in cervical cancer by counteracting microRNA-93-3p-dependent PEG3 downregulation.

Authors:  Yong-Jie Li; Zhe Yang; Yi-Ying Wang; Yue Wang
Journal:  Mol Oncol       Date:  2019-10-17       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.